Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Molecular Cell|January 24, 2002
Interaction between the bacterial iron response regulator and ferrochelatase mediates genetic control of heme biosynthesisZhenhao Qi, Mark R O'Brian
Microbiology (Reading, England)|April 4, 2000
Fur-independent regulation of iron metabolism by Irr in Bradyrhizobium japonicumIqbal Hamza, Zhenhao Qi, Natalie D King, et al.
Bioanalysis|October 8, 2016
Evaluation and selection of a non-PCR based technology for improved gene expression profiling from clinical formalin-fixed, paraffin-embedded samplesZhenhao Qi, Lisu Wang, Aiqing He, et al.
Plos One|January 26, 2013
Mutations in the hedgehog pathway genes SMO and PTCH1 in human gastric tumorsXi-De Wang, Hector Inzunza, Han Chang, et al.
The Journal of Molecular Diagnostics : JMD|July 1, 2019
Reliable Gene Expression Profiling from Small and Hematoxylin and Eosin-Stained Clinical Formalin-Fixed, Paraffin-Embedded Specimens Using the HTG EdgeSeq PlatformZhenhao Qi, Lisu Wang, Keyur Desai, et al.
Microcirculation (New York, N.Y. : 1994)|December 21, 2010
MEK5 is activated by shear stress, activates ERK5 and induces KLF4 to modulate TNF responses in human dermal microvascular endothelial cellsPaul R Clark, Todd J Jensen, Martin S Kluger, et al.
Archives of Pathology & Laboratory Medicine|September 19, 2024
Analytical and Clinical Validation of the Oncomine Dx Target Test to Assess HER2 Mutation Status in Tumor Tissue Samples From Patients With Non-Small Cell Lung Cancer Treated With Trastuzumab Deruxtecan in the DESTINY-Lung01 and DESTINY-Lung02 StudiesZhenhao Qi, Thomas Ha, Wenqin Feng, et al.
The Journal of Molecular Diagnostics : JMD|January 29, 2025
Analytical and Clinical Validation of the Plasma-Based Guardant360 CDx Test for Assessing HER2 (ERBB2) Mutation Status in Patients with Non-Small-Cell Lung Cancer for Treatment with Trastuzumab Deruxtecan in DESTINY-Lung01/02Zhenhao Qi, Shinya Tokuhiro, Justin I Odegaard, et al.
Investigational New Drugs|April 12, 2018
A multi-arm phase I dose escalating study of an oral NOTCH inhibitor BMS-986115 in patients with advanced solid tumoursKyaw L Aung, Anthony B El-Khoueiry, Karen Gelmon, et al.
Molecular Cancer Therapeutics|December 21, 2014
IRS2 copy number gain, KRAS and BRAF mutation status as predictive biomarkers for response to the IGF-1R/IR inhibitor BMS-754807 in colorectal cancer cell linesFei Huang, Han Chang, Ann Greer, et al.
Pageof 2